Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingAetna total-body CT screening Coverage Policy Upda…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0603

    Total-Body CT Screening

    Customize your policy alerts

    Sign up for Aetna Policy 0603 alerts

    Get alerted when Policy 0603 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy addresses the use and coverage stance for total-body (whole-body/full-body) CT screening and related ultrafast (electron-beam) CT screening, and applies to Aetna members and ordering providers.

    Policy Summary
    PayerAetna
    PolicyTotal-Body CT Screening
    Policy CodePolicy 0603
    Change TypeNo material change
    Effective DateMar 15, 2002
    Last ReviewSep 8, 2023
    Next Review DateJun 27, 2024
    Key ActionDo not approve total-body CT screening for asymptomatic or low-risk individuals because it is considered experimental/investigational and not a covered benefit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    experimental/investigationalCoverage stance
    S8092

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    HCPCS listed
    1,083REACT-2 enrollment
    1,192Community study size
    97%MGUS series NPV/spec

    Coverage Criteria and Policy Position

    inv-01: Experimental and Investigational

    Not covered (experimental/investigational):

    Primary coverage rule: Aetna considers total body (full-body/whole-body) CT screening or full-body ultrafast (electron-beam) CT screening experimental and investigational because it has not been shown to be effective as a screening test.

    Policy statement.

    inv-02: Trauma — selective coverage in high-risk patients

    Evidence-based coverage considerations for total-body CT in trauma:

    Trauma: potential coverage scenarios: Immediate total-body CT (iTBCT) may be appropriate for severely injured patients with high suspicion of multiple trauma or traumatic brain injury where rapid comprehensive imaging could affect management; randomized and cohort data show reduced ER time and suggest possible mortality or cost-effectiveness benefits in select subgroups (e.g., patients requiring emergency bleeding control interventions, multiple trauma, or TBI), but overall mortality benefit is not definitively proven.

    Based on REACT-2 trial and systematic reviews; subgroup findings limited by power.

    inv-03: MGUS / Smoldering MM — coverage with risk stratification

    Evidence-based coverage considerations for low-dose whole-body CT in plasma cell disorders:

    MGUS / SMM: when WBLD-CT is appropriate: Whole-body low-dose CT (WBLD-CT) or WB-CT (including as part of FDG-PET/CT) is appropriate as a first-line imaging modality to exclude myeloma bone disease in patients with high-risk MGUS or suspected smoldering multiple myeloma; if WB-CT/WBLD-CT or FDG-PET/CT is negative or inconclusive, whole-body MRI is recommended.

    Consistent with IMWG recommendations and UpToDate guidance; imaging may be omitted for low-risk MGUS (eg, IgG-type with M protein <1.5 g/dL and normal FLC ratio).

    Aetna considers total-body (full-body/whole-body) CT screening and full-body ultrafast (electron-beam) CT screening experimental and investigational because these approaches have not been shown to be effective as screening tests. Evidence reviews note limited data on accuracy and cost-effectiveness and emphasize a high ratio of false-positive to true-positive findings, with no demonstrated improvement in clinical outcomes for asymptomatic, low-risk populations.

    Routine whole-body CT screening is not recommended for asymptomatic, low-risk individuals, including those with low-risk MGUS without clinical concern for bone lesions. UpToDate guidance states imaging may be omitted for low-risk MGUS (e.g., IgG-type with serum M protein < 1.5 g/dL and a normal serum free light-chain ratio), and there are no data that total-body imaging improves outcomes in asymptomatic populations; therefore routine screening is excluded.

    Screening asymptomatic, low-risk individuals with total-body CT is considered not medically necessary due to lack of evidence of benefit and potential harms including radiation exposure, a high rate of incidental and false-positive findings, downstream unnecessary testing or procedures, and associated costs.

    Indiscriminate use of whole-body CT for general health screening in asymptomatic persons is not supported. Professional reviews advise against routine or indiscriminate application because of short-term risks (for example, contrast-related renal injury), long-term risks (radiation-induced cancer), high rates of false positives, and substantial cost.

    When Imaging May Be Appropriate

    inv-21: Trauma evaluation (contextual discussion, not a screening endorsement) — 1 top-level node

    Contextual discussion: Immediate/total-body CT may be used in the initial assessment of certain high-risk trauma patients; studies report reduced emergency department time with iTBCT versus selective imaging, but no consistent overall mortality benefit in non-randomized series.

    Contextual evaluation; not an endorsement for screening.

    inv-22: Immediate total-body CT for severe trauma/high-risk patients — 1 top-level node

    Severely injured/high-risk patients: Immediate total-body CT (iTBCT) may be considered for severely injured patients with high suspicion of multiple trauma or traumatic brain injury where rapid comprehensive imaging may change management; randomized data (REACT-2) showed a non-significant lower in-hospital mortality in a bleeding-control subgroup and cost-effectiveness analyses favor iTBCT in multiple trauma and TBI subgroups.

    Apply selection based on clinical severity and suspicion for injuries requiring urgent intervention.

    Coding and Billing

    Listed HCPCS codeHCPCS
    S8092Electron beam computed tomography (also known as ultrafast CT, cine CT)

    Provider Actions, Documentation, and Authorization

    Prior Authorization

    Prior authorization — not applicable for experimental/investigational TBCT

    Aetna considers total-body (full-body/whole-body) CT screening and full-body ultrafast (electron-beam) CT screening experimental and investigational and therefore not a covered benefit; prior authorization will not make these experimental services payable.

    Prior Authorization

    Selective prior authorization recommended for iTBCT in non-severe trauma

    Prior authorization is appropriate to ensure appropriate patient selection when immediate total-body CT (iTBCT) is considered for patients without documented severe trauma or clear indicators of multiple trauma/TBI, since benefit and cost-effectiveness are primarily supported in multiple trauma or TBI subgroups.

    • Consider authorization when iTBCT is ordered for patients without documented severe injury or without indicators of multiple trauma or traumatic brain injury.

    Prior Authorization Notes

    Note

    CT (total-body/full-body) — not covered

    Total-body (full-body/whole-body) CT screening is considered experimental and investigational and is therefore not a covered service; do not submit requests expecting coverage based on screening indication.

    Prior Authorization

    CT (total-body/iTBCT) — consider authorization for non‑severe trauma

    When iTBCT is ordered for trauma assessment, consider prior authorization if the patient does not have documented severe trauma or indicators of multiple trauma/TBI, since cost-effectiveness evidence favors use mainly in multiple trauma or TBI subgroups.

    • Prior authorization can be used to confirm the presence of documented severe injury or objective indicators of multiple trauma/TBI.

    Definitions

    Total-body CT screening definition (full-body / whole-body CT)
    TermTotal-body CT screening (also termed full-body or whole-body CT; includes full‑body ultrafast/electron‑beam CT)
    Typical scopeImaging of multiple body regions (commonly chest, abdomen, pelvis and potentially other regions) performed as a screening test in asymptomatic individuals
    Coverage stanceConsidered experimental and investigational; not covered as a screening test
    Representative HCPCS codeS8092 — Electron beam computed tomography (ultrafast CT, cine CT)
    WBLD-CT definition — whole-body low-dose CT for plasma cell disorders
    TermWhole‑body low‑dose CT (WBLD‑CT)

    Contrast Use Considerations

    Billing Rule

    Contrast administration — document risk/benefit and renal status

    Document contrast use decisions carefully: weigh the diagnostic benefit of contrast-enhanced whole-body CT against patient-specific risks and include justification for contrast administration in the record.

    • Record baseline renal function and rationale if administering IV contrast for whole‑body CT.
    • If contrast is withheld due to renal risk, document alternative imaging strategies.
    Billing Rule

    Contrast risk — balance renal injury risk against diagnostic need

    In trauma and other high‑risk patients, explicitly consider and document the risk of contrast-related renal injury when ordering contrast-enhanced whole‑body CT and balance this against the potential diagnostic benefit.

    • Assess and record renal function before contrast-enhanced whole‑body CT when clinically feasible.

    Services Not Covered

    Total-body CT screening (whole-body/full-body) and full-body ultrafast (electron-beam) CT screening for asymptomatic screening purposes are not covered as they are considered experimental and investigational and have not been shown to be effective as screening tests.

    Routine direct-to-consumer or general health full-body CT screening in asymptomatic, low-risk individuals is not covered. Evidence reviews recommend that low-risk asymptomatic individuals not undergo total-body imaging because of limited accuracy data, high false-positive rates, lack of demonstrated outcome benefit, and potential harms.

    Background and Context

    For-profit clinics have promoted ultrafast or total-body CT as a screening test, but no professional organization recommends whole-body CT for population screening of asymptomatic individuals. There are no published controlled trials demonstrating effectiveness of total-body CT as a screening test, and evidence reviews document frequent incidental findings, false positives, radiation exposure risks, and no proven improvement in clinical outcomes.

    Policy Summary
    PayerAetna
    PolicyTotal-Body CT Screening
    Policy CodePolicy 0603
    Change TypeNo material change
    Effective DateMar 15, 2002
    Last ReviewSep 8, 2023
    Next Review DateJun 27, 2024
    Key ActionDo not approve total-body CT screening for asymptomatic or low-risk individuals because it is considered experimental/investigational and not a covered benefit.
    SourceLink
    On This Page
    Coverage Criteria and Policy PositionWhen Imaging May Be AppropriateCoding and BillingProvider Actions, Documentation, and AuthorizationPrior Authorization NotesDefinitionsContrast Use ConsiderationsServices Not CoveredBackground and Context

    inv-23: Low-dose whole-body CT for MGUS/SMM work-up — 1 top-level node

    Indication for WBLD-CT in hematologic work-up: Perform whole-body low-dose CT (WBLD-CT) or WB-CT/FDG-PET/CT as the first-line imaging test to exclude myeloma bone disease in patients with high-risk MGUS or suspected smoldering multiple myeloma; if these studies are negative or inconclusive, obtain whole-body MRI. Omit imaging in low-risk MGUS per guideline criteria.

    Reflects IMWG and UpToDate recommendations.

    Documentation Required

    Document specific clinical indication for whole‑body imaging

    Provide clinical justification that matches the intended use of whole-body imaging (e.g., specify suspected condition such as high-risk MGUS, smoldering MM, or the clinical suspicion of multiple trauma) and include relevant objective findings.

    • Document the specific clinical indication prompting whole-body imaging.
    • Include objective risk factors or exam findings that support use of WB-CT or iTBCT.
    Step Therapy

    Stepwise imaging sequence for MGUS / SMM work-up

    When evaluating patients for suspected smoldering multiple myeloma or high-risk MGUS, perform whole-body low-dose CT (WBLD-CT) or WB-CT/FDG-PET/CT first; if these studies are negative or inconclusive and clinical suspicion remains, proceed to whole-body MRI per IMWG recommendations.

    • WB-CT or FDG-PET/CT as first-line imaging for suspected SMM or high-risk MGUS.
    • If WB-CT / FDG-PET/CT is negative or inconclusive, obtain whole-body MRI next.
    Documentation Required

    Documentation expectations — code and report details

    Include HCPCS code S8092 where applicable (electron beam CT) and document findings and any recommendations resulting from screening or diagnostic whole-body imaging, noting that large screening series commonly report many incidental findings and follow-up recommendations.

    • List HCPCS S8092 when electron-beam CT is performed.
    • Document all significant imaging findings and any recommended additional evaluations.
    Documentation Required

    Include clinical risk stratification and justification

    Clinical documentation should include patient risk stratification and objective measures relevant to the indication (for example, MGUS risk level or laboratory cutoffs, trauma severity including GCS, or specific suspicion for multiple myeloma/bone disease).

    • For MGUS: record risk features (e.g., M protein level, free light chain ratio) when applicable.
    • For trauma: document severity indicators such as Glasgow Coma Scale or mechanism of injury.
    • State the level of clinical suspicion for multiple myeloma or bone involvement.
    Denial Risk

    Denial trigger — TBCT screening not covered

    Requests for total-body CT screening or full-body ultrafast (electron-beam) CT screening for screening purposes will be denied as these services are considered experimental and investigational and are not covered.

    Denial Risk

    Risks of indiscriminate whole‑body CT use

    Be aware that indiscriminate use of whole-body CT is discouraged because of short-term risks (contrast-related renal injury), long-term risks (radiation-induced cancer), and high costs; overuse may lead to noncoverage decisions based on medical necessity.

    • Balance the diagnostic need against risk of contrast nephrotoxicity in patients receiving contrast-enhanced studies.
    • Consider radiation exposure and downstream costs when ordering whole-body CT.
    Intended useAssessment to exclude myeloma bone disease in patients with plasma cell disorders (e.g., high‑risk MGUS, suspected smoldering multiple myeloma)
    Clinical roleRecommended by IMWG as first‑line imaging (WB‑CT or as part of FDG‑PET/CT) for high‑risk MGUS / suspected SMM; follow with whole‑body MRI if negative or inconclusive
    Performance noteIn a retrospective MGUS series (n=71), bone marrow attenuation assessment by WBLD‑CT had specificity and negative predictive value of 97%
    iTBCT definition — immediate total-body CT during initial trauma assessment
    TermImmediate total‑body CT (iTBCT)
    Intended useRapid comprehensive CT performed during the initial trauma assessment for patients with suspected severe injury (multiple trauma or TBI)
    Evidence summaryRandomized (REACT‑2) and economic studies evaluated iTBCT versus selective CT; subgroup and cost‑effectiveness data suggest potential benefit in multiple trauma and TBI patients but overall mortality benefit was not definitively proven
    Key trial dataREACT‑2 enrolled 1,083 patients; among 172 who underwent emergency bleeding control, in‑hospital mortality was 12.9% with iTBCT vs 24.1% with standard work‑up (p=0.059)
  1. Document the clinical rationale if contrast is used despite elevated renal risk.